Bio

Rob Abrams has over 27 years of experience in biomedical device product development, research, operational management, new business development and strategic investments. Rob joined Sanderling as an Operating Partner in April 2008. Prior to joining Sanderling, Rob served 12 years at Boston Scientific Corp. as Group Vice President of New Business Development for BSC’s Cardiovascular Group Divisions, which included Neurovascular, Cardiac Surgery, Neuromodulation, Electrophysiology, and Peripheral Interventional Divisions. In this role, he also served on executive management boards, and patent and legal review boards. During his tenure at BSC, Rob completed acquisition of Smart Therapeutics, Inc. for intracranial stents, and other minimally invasive access devices, Precision Vascular Systems, Inc. a steerable guidewire/catheter company, and several neuromodulation companies, including acquisition of Advanced Bionics Corp. He also led the corporate program to explore technology for acute ischemic stroke therapy, and transacted several investments in that realm. Rob had become a part of BSC via their acquisition of Target Therapeutics, where he was Director of New Business Development from July 1996. Prior to joining Target, Rob was Director of Product Development for LocalMed, Inc., a start-up dedicated to devices for catheter-based local drug delivery in cardiac vasculature. From 1988 through 1995, Rob served various roles at Guidant Corporation in their Cardiovascular Business. He served as Director of R&D for the intrapreneurial Guidant Division, Heart Rhythm Technologies, developing devices for EP cardiac arrhythmias. Earlier, at Guidant’s Advanced Cardiovascular Systems (ACS) Division, he contributed to the product development and launch of guidewires, balloon catheters and stent technologies for interventional cardiology. At ACS, he was a prolific inventor, pioneering the fabrication and use of Nitinol superelastic alloy in many novel medical technologies. Overall, Rob has 65 patents in medical devices. Prior to ACS, Rob’s entry into medical technology began at Howmedica Orthopedics, where he contributed to new bone in-growth technologies for hip and knee replacement prosthetic devices. Rob received his Bachelor of Science in Biomedical Engineering and Materials Science Engineering from the University of Pennsylvania, graduating summa cum laude.